Limits...
Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors.

Yoshimoto M, Kurihara H, Fujii H - ScientificWorldJournal (2015)

Bottom Line: During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy.However, clinical use of these new drugs presents unexpected adverse effects or poor therapeutic effects.Although immunohistochemical, polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) analyses of biopsy samples are conventional and popular for this diagnostic purpose, molecular imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are also useful for noninvasive estimation of gene and protein expression and drug pharmacokinetics.

View Article: PubMed Central - PubMed

Affiliation: Division of Functional Imaging, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.

ABSTRACT
During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy. However, clinical use of these new drugs presents unexpected adverse effects or poor therapeutic effects. Therefore, we require diagnostic tools to estimate the target molecule status in cancer tissues and predict therapeutic efficacy and adverse effects. Although immunohistochemical, polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) analyses of biopsy samples are conventional and popular for this diagnostic purpose, molecular imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are also useful for noninvasive estimation of gene and protein expression and drug pharmacokinetics. In this review, we introduce new radiolabeled TKIs, antibodies, and their clinical application in molecular targeted therapy and discuss the issues of these imaging probes.

No MeSH data available.


Related in: MedlinePlus

Depiction of tumor angiogenesis. Angiogenesis is an important tumor growth factor. Vascular endothelial cell proliferation is essential for the development of new blood vessels.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4385703&req=5

fig3: Depiction of tumor angiogenesis. Angiogenesis is an important tumor growth factor. Vascular endothelial cell proliferation is essential for the development of new blood vessels.

Mentions: Antiangiogenic therapy is a cancer treatment strategy [32, 33]. Angiogenesis consists of various processes such as the secretion of angiogenic factors and the proliferation of vascular endothelial cells (ECs; Figure 3). Bevacizumab is a monoclonal anti-VEGF antibody that inhibits VEGF-stimulated EC proliferation [34, 35]. Vandetanib, a VEGFR-TK inhibitor, directly inhibits EC proliferation because VEGF expression is upregulated within tumor tissues [36, 37]. Antiangiogenic drugs directly or indirectly inhibit EC proliferation followed by tumor suppression. Therefore, to decide the therapeutic plan using antiangiogenic drugs, we should estimate the expression level of the target molecule, but not the biological activity of tumor cells.


Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors.

Yoshimoto M, Kurihara H, Fujii H - ScientificWorldJournal (2015)

Depiction of tumor angiogenesis. Angiogenesis is an important tumor growth factor. Vascular endothelial cell proliferation is essential for the development of new blood vessels.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4385703&req=5

fig3: Depiction of tumor angiogenesis. Angiogenesis is an important tumor growth factor. Vascular endothelial cell proliferation is essential for the development of new blood vessels.
Mentions: Antiangiogenic therapy is a cancer treatment strategy [32, 33]. Angiogenesis consists of various processes such as the secretion of angiogenic factors and the proliferation of vascular endothelial cells (ECs; Figure 3). Bevacizumab is a monoclonal anti-VEGF antibody that inhibits VEGF-stimulated EC proliferation [34, 35]. Vandetanib, a VEGFR-TK inhibitor, directly inhibits EC proliferation because VEGF expression is upregulated within tumor tissues [36, 37]. Antiangiogenic drugs directly or indirectly inhibit EC proliferation followed by tumor suppression. Therefore, to decide the therapeutic plan using antiangiogenic drugs, we should estimate the expression level of the target molecule, but not the biological activity of tumor cells.

Bottom Line: During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy.However, clinical use of these new drugs presents unexpected adverse effects or poor therapeutic effects.Although immunohistochemical, polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) analyses of biopsy samples are conventional and popular for this diagnostic purpose, molecular imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are also useful for noninvasive estimation of gene and protein expression and drug pharmacokinetics.

View Article: PubMed Central - PubMed

Affiliation: Division of Functional Imaging, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.

ABSTRACT
During the past decade, the efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, and molecular targeted therapies have become the mainstream in cancer therapy. However, clinical use of these new drugs presents unexpected adverse effects or poor therapeutic effects. Therefore, we require diagnostic tools to estimate the target molecule status in cancer tissues and predict therapeutic efficacy and adverse effects. Although immunohistochemical, polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) analyses of biopsy samples are conventional and popular for this diagnostic purpose, molecular imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are also useful for noninvasive estimation of gene and protein expression and drug pharmacokinetics. In this review, we introduce new radiolabeled TKIs, antibodies, and their clinical application in molecular targeted therapy and discuss the issues of these imaging probes.

No MeSH data available.


Related in: MedlinePlus